diabetic macular edema
Conditions
Interventions
None listed
Sponsors
Department of Ophthalmology, Mie University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All of the patients had received IVTA combined with phacoemulsification and aspiration cataract surgery and intraocular lens implantation between December 2014 and December 2016. The inclusion criteria were patients who were resistant to previous treatments such as retinal photocoagulation, intravitreal injections of anti-VEGF agents, or sub-tenon triamcinolone acetonide injections(STTA), had a medical history of systemic diseases such as myocardial infarction, cerebral infarction, or cerebral hemorrhage, and had financial difficulty in paying for the anti-VEGF treatments. The CRT of all the patients was over 300 um as determined by fluorescein angiography(FAG)and optical coherence tomography(OCT). A recurrence was defined as an increase in the CRT by 20% compared to the minimum CRT value during the observation period.
Exclusion criteria
Exclusion criteria: Patients were excluded if they had the macular traction syndrome, active proliferative diabetic retinopathy, uveitis, poorly controlled ocular hypertension, glaucoma, had intraocular surgery within the past 6 months, and history of anti-VEGF treatment or STTA, or had macular photocoagulation within the past 3 months before the beginning of the treatment. Patients who had adverse reactions to steroids were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual acuity after treatment | — |
Countries
Japan
Contacts
Public ContactMasahiko Sugimoto
Mie University Graduate School of Medicine Department of Ophthalmology
Outcome results
None listed